The Defense Health Agency awarded Mayo Clinic $140,000 on November 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to conduct targeted disruption of translation for NUT carcinoma. Work is performed in Rochester, Minnesota, with an expected completion date of October 31, 2028. The award supports basic and applied biomedical research intended to transform healthcare for Service Members and the American public through innovative research and investigation of medical solutions relevant to military health priorities.